Cadila gets USFDA nod for Divalproex

 According to a release issued by Cadila to the BSE today, the product, which is an equivalent of Valproic Acid, is an anti-convulsant and falls in the CNS segment. "The drug will go off patent in January 2008. The annual sales of Divalproex Sodium DR tablets as per IMS in 2004 in the US market was estimated at $680 million," the release added.